Novo Nordisk says Victoza provides greater HbA1c reductions than SGLT2 inhibitors

Novo Nordisk announced findings from a network meta-analysis showing that Victoza (liraglutide) provided greater HbA1c reductions compared to oral SGLT2 inhibitors in people with type 2 diabetes. The study, presented at the World Diabetes Congress, compared the injectable GLP-1 analogue to Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin), Johnson & Johnson's Invokana (canagliflozin) and AstraZeneca's Farxiga (dapagliflozin).

The analysis included 17 randomised controlled trials and included people with type 2 diabetes who were inadequately controlled with metformin alone or in combination with sulfonylurea, DPP4 inhibitors or thiazolidinedione. Novo Nordisk noted that results also showed that Victoza provided an improved likelihood of reaching glycaemic goals compared to the SGLT2 inhibitors.

"In the absence of head-to-head trials, this analysis provides valuable insight into the comparative outcomes with [Victoza] versus SGLT2 inhibitors in people with type 2 diabetes uncontrolled on oral antidiabetic treatments," remarked lead author Maria Lorenzi.

Victoza was approved in the EU in 2009 and is marketed in over 80 countries, generating revenue of about $2.4 billion last year. However, sales of the therapy have come under threat from oral drugs, with Bloomberg Intelligence analyst Sam Fazeli noting that recent findings for Jardiance could delay the use of Victoza. In September, Eli Lilly and Boehringer Ingelheim announced that Jardiance reduced the risk of heart attacks, strokes and cardiovascular deaths in people with diabetes and a high risk of heart problems (for related analysis, read ViewPoints: Eli Lilly sees immediate boost in Jardiance sales).

Novo Nordisk chief scientific officer Mads Krogsgaard Thomsen said that the company is conducting its own trial, called Leader, on cardiovascular outcomes with Victoza, with results set to be announced as early as the first quarter of 2016.

For more information on the diabetes market, see Type 2 Diabetes Mellitus: KOL Insight.

To read more Top Story articles, click here.